This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heartfailure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with HeartFailure with PreservedEjectionFraction (HFpEF).
Background and aims The independent role of body fat distribution and fat-free mass in heartfailure (HF) risk is unclear. Overall, HF risk was more strongly associated with central adiposity (waist circumference (WC) adjusted for body mass index (BMI); HR 1.38, 95% CI 1.32 years, 44% male) from the UK Biobank. to 2.07).
Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%72%). Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%72%). Circulation, Ahead of Print.
What is the incremental benefit in patients with heartfailure and preservedejectionfraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) ≥27?
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heartfailure (HF) with preservedejectionfraction (HFpEF). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased.
Background: Patients with heartfailure, a preservedejectionfraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heartfailure. n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5, n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5,
Background:Patients with heartfailure (HF) with preservedejectionfraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg or placebo for 52 weeks.
Hypertensive disorders of pregnancy as a risk factor for heartfailure. BMI, body mass index; CV, cardiovascular; CVD, cardiovascular disease; HELLP, haemolysis, elevated liver enzymes, low platelet count.
The H2FPEF score and probability were developed to assist in heartfailure with preservedejectionfraction (HFpEF) diagnosis. Results:Overall, 140 participants were identified (age: 56±16 years; BMI: 30.04±8.04 kg/m2; 74% female) with normal left ejectionfraction (LVEF: 63±9%).
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heartfailure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] to 25 kg/m2) and underweight (BMI less than 18.5 kg/m2) or severe obesity (BMI greater than 40 kg/m2).
BMI, body mass index; GLS, global longitudinal strain; LASct, left atrial contractile strain. Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heartfailure with preservedejectionfraction.
Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heartfailure that has had few therapeutic options. It also lowered their systolic blood pressure and waist circumference.
A multivariate logistic regression model was used to assess for statistically significant differences after controlling for potentially confounding variables including age, sex, BMI, AF, prior MI, COPD, DM, HTN, serum creatinine, and NYHA functional class.Results:A total of 320 patients were included in this analysis, with 230 on BB (72%).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
75 
Let's personalize your content